Phase 2 results presented at ASCO Genitourinary show the HER2‑targeted antibody‑drug conjugate disitamab vedotin (DV) delivered confirmed overall response rates above 50% in both HER2‑positive and HER2‑low cohorts of previously treated metastatic urothelial carcinoma. The trial reported median progression‑free survival of about 5.7 months in both groups and promising overall survival signals. The RC48G001 study evaluated DV monotherapy in patients who had received one or two prior systemic therapies, including platinum agents. DV combines a HER2 antibody with the MMAE payload; investigators noted response parity between HER2‑high and HER2‑low tumors, raising questions about bystander effects and patient selection strategies. What happened: DV produced high objective response rates across HER2 expression levels in a hard‑to‑treat population. Why it matters: the data position another ADC as a potential entrant in advanced urothelial cancer where approved HER2 options remain limited, prompting global development interest and potential registration pathways outside markets where DV has existing data.